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Abstract
Background: This study examines sex differences in substance use and substance use disorder in the acute
psychiatric department, and possible interactions between sex and clinical and social factors associated with this
phenomenon.
Methods: Data concerning substance use were collected in a naturalistic cohort study (n = 384, 51.6% male, 48.4%
female) in an acute psychiatric department. Recent intake of substances at admission, diagnosis of substance use
disorder and demographic and socioeconomic information were recorded. At admission, serum and urine samples
were analysed for substance use and breath analysis was performed for alcohol levels.
Results: Twice as many men as women were diagnosed with substance use disorder, whereas there were no gender
differences in the number of positive toxicology screenings. Toxicology screening revealed the use of non-prescribed
medication with addiction potential in 40% of both female and male patients many of whom did not report this in the
admission interview. A low level of education in men and absence of parental responsibility in women showed a
statistically significant interaction with a current diagnosis of substance use disorder.
Conclusions: Despite no sex differences in positive toxicology screenings in the acute psychiatric department, twice as
many men as women are diagnosed with substance use disorders. The use of prescription drugs with addiction
potential was widely under-reported by both sexes, in patients with no prescriptions for the medications. Women with
no parental responsibility are overrepresented among those diagnosed with substance use disorder, as are men with a
low level of education.
Trial registration: The study is registered with the ClinicalTrials.gov identifier NCT01415323
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Background
Concurrent substance use and substance use disorders
are prevalent among patients in acute psychiatry [1–6].
Clinical studies have consistently found that people with
mental illness and concurrent substance use disorders
have a more severe course of illness [7], and also an
increased risk of premature death [8]. Despite the high
relevance of substance use occurring in combination
with mental illness, substance use disorders are often re-
ported to be under-detected in the psychiatric popula-
tion [9–12]. People with both disorders are shown to
have difficulties accessing help for either of the condi-
tions [13]. Also, they are vulnerable to poorer treatment
responses and outcomes in the long run [7, 10, 14, 15].
There is a discordance between the number of males
and females who are undergoing addiction treatment.
Women with substance use disorders are less likely to
enter treatment compared with male substance users
[16–18]. Globally, despite the fact that one out of three
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drug users is female, only one out of five in treatment is
female [19]. In Norway, one out of two substance users
is female; yet, females constitute only one third of the
patients in Norwegian addiction treatment facilities [20].
The reason behind this gender discordance is uncertain,
but may be related to both a less severe substance use in
women that does not fill the criteria for a diagnosis, and
also to social and structural barriers [16, 19].
Although there is still a male dominance in substance
use [21, 22], women in developed countries have
increased both the frequency and quantity of their sub-
stance use over recent decades [21–23]. The gender gap
in substance use has narrowed particularly among the
youngest cohorts [23]. Compared with men, women are
found to be more vulnerable to adverse medical, psychi-
atric and social consequences from substance use [17].
With respect to the use of alcohol, cannabis and opioids,
women are also found to be vulnerable to developing an
accelerated progression from moderate use to substance
use disorders [16, 24]. An exception to the observed pat-
tern of male dominance in substance use is that a higher
proportion of females use prescription drugs with addic-
tion potential [3, 7, 25]. Women with mental illness also
have particularly high comorbidity rates for sedative
hypnotics and opioid use disorders resulting from pre-
scription drugs as compared to men [26, 27].
Identification of substance use disorders creates the
basis to plan addiction treatment. The first contact with
specialised health care services for many patients with
substance use combined with psychiatric disorders is the
psychiatric acute and emergency services. It is important
to evaluate the quality of this clinical examination and to
investigate whether the reported gender-gap is present
in these clinical settings.
One starting point for investigating the reasons behind
the observed sex differences in the identification of sub-
stance use is the procedures for admissions to acute psy-
chiatric departments. The diagnosis of substance use
disorders in acute admissions is an ongoing process
from admittance to discharge. Often, the diagnosis is
established at the initial evaluation, based on self-
reported information, physical examination and labora-
tory testing. The primary aim of this study was to
examine sex differences in substance use and substance
use disorder in the psychiatric acute department, and
how sex interacts with possible clinical and social factors
associated with this phenomenon.
Methods
Setting
The Norwegian acute psychiatric services are public and
catchment area based. St Olavs University Hospital,
Department of Acute Psychiatry, is situated in the
county of Sør-Trøndelag in central Norway. All patients
in the catchment area ≥ 18 years with acute psychiatric
conditions in need of hospitalisations are admitted to
this department. Patients with only substance use disor-
ders are admitted to other, separate facilities. The basis
for acute psychiatric hospitalisations is short-term
admissions [3]. The median length of stay in the present
data material was six days.
The patients were examined on arrival at the psychi-
atric department by the physician on duty, during the
first day by specialist in psychiatry or in clinical psych-
ology, and a number of times during in-patient stay by
specialists or residents in psychiatry.
Sample
Acutely admitted inpatients were consecutively asked to
participate in a study where investigation of substance
use was both part of the study procedure and the clinical
routine in the department [28]. A total of 795 patients
were admitted to the hospital during the study period, of
which 424 (53.7%) were included in the study. Based on
the predefined inclusion criteria, 14 patients (1.8%) were
excluded, while 150 (18.9%) were discharged from the
hospital before they could be asked to participate, and
204 (25.7%) refused to participate. Where respondents
were admitted more than once, only data from the first
admittance were included. Data from 384 unique
respondents requiring hospitalisations between September
1st, 2011 and March 31st, 2012 were included in the
material. Some patients in acute psychiatric departments
have limited capacity to understand information about
clinical studies at admission. To ensure that the patients
understood the information, written, informed consent
was collected by a specialist in psychiatry or clinical
psychology the first day after admission. The study is regis-
tered with the ClinicalTrials.gov identifier NCT01415323.
Ethical approval was obtained from the Regional Ethical
Committee, Central Norway (2011/137).
Measures
Primary measures were 1) recent intake of substances at
admission and 2) diagnosis of substance use disorder.
The physicians assessing recent intake of substances in
the admission interview completed a study form with
two questions, one on current drug influence, and, the
other on substance use during the preceding week. The
questions were formulated as follows: Based on all avail-
able information at the time of clinical assessment: 1) In
your opinion, is this patient under the influence of drugs
or alcohol at admission (tick off ): Not at all, mildly,
moderately, markedly, or uncertain? 2) Is there any in-
formation on recent substance intake (tick off ): benzodi-
azepines, opiates, amphetamines, cannabis, cocaine,
alcohol, others, or none? The physician based this evalu-
ation on information from the referral form and by
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questioning the patients about recent use of the different
substances. Breath analysis for estimation of blood alco-
hol levels was administered by staff during the admission
interview (valid tests n = 244, 63.5%). Serum and urine
samples were collected as soon as possible within the
first 24 hours after admission (valid screens n = 342,
89%). Substances analysed in urine samples were alcohol,
stimulants, opioids and cannabis, and in serum samples
the substances were benzodiazepines and derivatives, z-
drugs and opioids. On-site urine tests were not used due
to the limited accuracy of the method [29]. Samples were
analysed by the local clinical pharmacology laboratory
using a liquid chromatography mass spectrometry (LC-
MS) method. For most patients the results of these tests
were not available to the clinicians at discharge.
Diagnoses according to ICD-10 criteria for research [30]
were set at discharge in a weekly consensus meeting
including the patients therapist and specialists (clinical psy-
chologists or psychiatrists) of whom at least one had per-
sonally examined the patient. After discharge, the medical
records for all the respondents were examined for all previ-
ous diagnoses of substance use disorders. Diagnoses of
substance use disorders were categorised by: 1) prescrip-
tion drugs (sedative hypnotics and opioids); and, 2) alcohol;
and 3) illegal drugs (cannabis, stimulants and opioids).
Recent intake of substances at admission was mea-
sured by the following statements: 1) Respondent was
assessed as influenced by substances during medical
examination at admission (influence of substances at ad-
mission); or 2) if there were reported recent substance
intake (reported recent substance intake); or 3) sub-
stance use was asserted by breath-, urine- or serum toxi-
cology screens (positive toxicology screening).
The following baseline measures were included as
covariates: demographic and socioeconomic information
(sex, age by quartiles, employment, education (primary
school, 10 years of schooling; high school, 13 years of
schooling; or higher education, such as college or uni-
versity degrees), parental responsibility for minors, and
whether living with a partner). Also included as covari-
ates were any previous hospitalisations in psychiatric
departments, legal status of admission (voluntary/co-
erced), and previously diagnosed substance use disorder.
Statistical analysis
Statistical analysis of the data was performed using the
Statistical Package for the Social Sciences (IBM, SPSS,
version 21). The study sample was described by sex and
diagnoses of substance use disorders, and use of chi
square tests for categorical variables. The continuous
variable age was not normally distributed (skewed to the
left) and was, therefore, categorised by quartiles.
We used a model built on crude analysis of substance use
disorder by sex and the data describing the respondents.
The interactions studied made use of statistically significant
sex differences from chi square tests and was further ana-
lysed by logistic regression. The value that, on a theoretical
base was assumed to have the lowest association with sub-
stance use disorders was used as a reference (e.g. parental
responsibility, higher education and no previously diag-
nosed substance use disorder). P-values for women or men
from the crude analysis ≤ .05 were analysed further in the
adjusted logistic regression analysis (sex*statistical signifi-
cant variables for women or men) to assess whether the
relation between the specific factors and incidence of sub-
stance use disorder was overrepresented in women or men.
Results
Clinical and social description of the sample by sex and
substance use disorder is summarised in Table 1. More
men than women diagnosed with substance use disorders
in the current hospitalisation had parental responsibility
for minors (27.4% and 8.9%, respectively) and had no
more education than primary school (55.8% and 44.4.% re-
spectively). The overrepresentation of men with substance
use disorder and low education level was statistical signifi-
cant in the adjusted analysis (p = .009), as was the female
overrepresentation of substance use disorder if there was
no parental responsibility (p < .000).
Overall, there was male dominance in all the different
measures of substance use (Table 2). The only exception
was the equal distribution of physicians’ assessment of
intoxication at admission (22% for women and 27% for
men, p = .295) and distribution of positive toxicology
screenings in breath, urine and serum that showed simi-
lar numbers between sexes (49% and 52%, p = .544).
Male dominance in recent substance use at admission
and previously and new diagnoses of substance use dis-
orders was statistically significant.
Positive toxicology screening, reported recent sub-
stance intake, and diagnoses of substance use disorders
were almost identical for men (52%, 50% and 46.5%). By
contrast, females received almost twice as many positive
screening results with regard to reports on their recent
substance intakes and diagnoses of substance use
disorder (48.9%, 28.8%, and 23.7%).
Toxicology screening revealed the use of non-
prescribed medication with addiction potential in 40% of
both sexes (43.7% in women and 36.3% in men). Benzo-
diazepines constituted the largest group of positive test
results for drugs without prescription for both women
and men (Table 3).
Discussion
The main finding in the present study is that in spite of
similar percentages of positive toxicology screenings be-
tween women and men (48.9% and 52%, respectively),
diagnoses of substance use disorders were twice as
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prevalent in men. The prevalence of diagnoses of sub-
stance use disorders in our study was in line with recent
findings, which reported a prevalence of 30–65% of such
diagnoses in acute psychiatry (1–6).
Fløvig et al. [3], in a study from the same catchment
area, presented numbers for the gender distribution of
recent substance intake in acute psychiatry, and, based
on similar laboratory testing, reported a recent sub-
stance intake in 83% of females and 80% of males. They
reported a positive diagnosis of substance use disorders
in 50% of males, but only in 16% of the females. Com-
pared with our study, the percentages of recent sub-
stance intakes prior to admission and diagnoses of
substance use disorders in men were similar, but the rate






Variable n (%) n (%) x2 p
Previously diagnosed SUD 35 (18.8%) 71 (35.9%) 13.369 < .001*
Assessed as influenced by substances at admission 41 (22%) 53 (26.8%) 1.095 .295
Reported recent substance intake 58 (28.8%) 99 (50) 18.413 < .001*
Positive toxicology screening 91 (48.9%) 103 (52) .368 .544
Diagnosed SUD at discharge 44 (23.7%) 92 (46.5) 24.485 < .001*
• Alcohol use disorder 22 (11.8%) 38 (19.2) 4.610 .032*
• Prescription drug use disorder 7 (3.8%) 5 (2.5) .019 .890
• Illegal drug use disorder 15 (7.6%) 49 (24.8) 20.329 < .001*
(%) within gender. Calculations of ratio. x2 estimated by Pearson’s chi-squared test. Significance level p ≤ .05, * statistically significant. SUD substance use disorder
Table 1 Characteristics of respondents by sex and SUD
Characteristics Total Women Men Interactions
SUD SUD SUD
Yes No Yes No Yes No
n (%) n (%) p1 n (%) n (%) p1 n (%) n (%) p1 p
Age, quartiles
• 18–25 38 (27.1) 58 (23.9) 15 (33.3) 37 (26.2) 23 (24.2) 21 (20.6)
• 26–37 38 (27.1) 59 (24.3) 14 (31.4) 35 (24.8) 24 (25.3) 24 (23.5)
• 38–49 43 (30.7) 55 (22.6) 12 (26.7) 29 (20.6) 31 (32.6) 26 (25.5)
• 50 + 21 (15) 71 (29.2) .045 4 (8.9) 40 (28.4) .067 17 (17.9) 31 (30.4) .224
Marital status
• Living with a partner 25 (17.9) 69 (28.7) 8 (17.8) 38 (27.3) 17 (17.9) 31 (30.7)
• Living alone 115 (82.1) 171 (71.3) .144 37 (82.2) 101 (72.7) .120 78 (82.1) 70 (69.3) .420
Parental responsibility
• Yes 30 (21.4) 64 (26.3) 4 (8.9) 37 (28.1) 26 (27.4) 27 (26.5)
• No 110 (78.6) 179 (73.7) .048* 37 (91.1) 104 (71.9) .013* 69 (72.6) 75 (73.5) .887 <.001*
Education
• Primary school 73 (52.1) 94 (39.2) 20 (44.4) 57 (41) 53 (55.8) 37 (36.6) .001*
• High school 53 (37.9) 106 (44.2) 18 (40) 61 (43.9) 35 (36.8) 45 (44.6) <.001*
• College/university 14 (10) 40 (16.7) .029* 7 (15.6) 21 (15.1) .806 7 (7.4) 19 (18.8) .009* -
Employment
• Labour 38 (29.7) 46 (20.7) 12 (28.6) 29 (22.7) 26 (30.2) 17 (18.1)
• Benefits/pension 90 (70.3) 176 (79.3) .069 30 (71.4) 99 (77.3) .533 60 (69.8) 77 (81.9) .079
Legal status, admission
• Coercion 41 (29.3) 46 (19.2) 14 (31.1) 26 (18.8) 27 (28.4) 20 (19.8)
• Voluntarily 99 (70.7) 193 (80.8) .031* 31 (68.9) 112 (81.2) .098 68 (71.6 81 (80.2) .182
p1 estimated by Pearsons chi square tests. Interaction test by bivariate (a*b) logistic regression. Significance level p ≤ .05
* statistically significant SUD substance use disorder
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for females with positive diagnoses of substance use dis-
orders was lower, although the differences did not reach
statistical significance. In both Fløvig et al. and the
present study, when positive toxicology screening results
were considered, there was a discordance between sub-
stance use disorder diagnoses and recent substance
intake, which was especially pronounced in females. This
may have been caused by substance use not fulfilling the
ICD-10 criteria for research for substance use disorder,
or a bias in diagnosing women with substance use
disorder [16].
Another reason behind the discordance may be the
different patterns of substance use. Use of medication
with addiction potential was widely under-reported in
both sexes, given that 40% of positive toxicology screen-
ings were from patients with no prescriptions for the
medications, and many without self-report of recent
intake. The prevalence of non-prescribed use of medica-
tion with addiction potential has previously been
reported to be 15–36% of positive toxicology screenings
in acute psychiatry [3, 31]. Our study showed less agree-
ment between self-report of recent substance intake and
toxicological screenings in acute psychiatric settings than
that earlier reported.
Social factors are known barriers for women in under-
going addiction treatment [16, 19]. The same barriers
may be relevant in diagnosing substance use disorders in
females in acute psychiatry. We found that parental
responsibility for minors was three times more prevalent
among men diagnosed with substance use disorders then
women (27% and 9% respectively, p = .013). This may
reflect the manner in which parental responsibility and
substance use by females are interpreted by the acute
psychiatric services and the stigma that surrounds the
issue. Female patients themselves may inhibit the discov-
ery of problematic substance use. Caring for children
may result in a need for child-care if the patient accepts
treatment, but it may also increase a risk of reactions
from the child-welfare authorities. Parental responsibility
can therefore be a barrier to admitting substance abuse
by females, and also an impediment to the diagnosis of
substance use disorders. Another possible explanation
for differences between the sexes in diagnosis may be
the biased opinion of the health care professionals
regarding the role of males and females in parenting.
The stigma associated to substance use may be a hin-
drance for addiction treatment for women [32, 33].
Stigma may discourage women from admitting sub-
stance use and further raise an obstacle to the diagnosis
of substance use disorders in women using acute psychi-
atric services.
The higher comorbidity of PTSD, eating disorders,
depression and anxiety in women has been suggested as
the reason prompting women to seek help primarily for
conditions other than substance use [16]. The interpret-
ation of the meaning of the substance use, both by the
women themselves and by professionals in acute psych-
iatry, may influence the reporting of lower rates of diag-
nosed substance use disorders in women [16, 18]. The
acute use of substances can be interpreted as a (destruc-
tive) way of handling the mental stress suffered by
females in psychiatric crises, rather than as a problem
inextricably connected with the use of the substance
itself [16]. Women and men in acute psychiatry with
positive evidence of recent substance use at admission
may not always qualify for a diagnosis of substance use
disorder. Moreover, we need to reveal the evidence of
substance use in order to assess the issue, especially
when dealing with non-prescribed prescription drugs.
Strengths and limitations
Deficiencies may exist in the data. The study sample was
of moderate size, which may limit generalisability. The
inclusion of subjects in this study was based on
informed consent. The possibility of implicit selection of
respondents may be relevant in research on substance
use, as we do not know whether non-consenting patients
and patients in other centres would exhibit different
characteristics on the variables of interest. Validated
screening instruments for detection of problematic sub-
stance use were not used in the clinical interview and









(% of positive tests)
At least one of the following 90 (48.4%) 38 (43.7%) 88 (43.4%) 33 (36.3%)
Benzodiazepine derivatives 59 (31.7%) 25 (42.4%) 60 (30.3%) 25 (41.6%)
Zopiclone 23 (12.4%) 9 (39.1%) 17 (8.6%) 4 (23.5%)
Morphine 3 (1.6%) 1 (33.3%) 2 (1%) -
Codeine 5 (2.7%) 3 (60%) 6 (3%) 1 (16.6%)
Methadone - - 3 (1.5%) 3 (100)
()% within sex and within positive tests
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this may have led to the exclusion of potentially identifi-
able problematic substance use.
However, the use of consecutively admitted acute
patients from one catchment area strengthens the gener-
alisability of the study. The representativeness is also
strengthened by the preclusion of exclusion criteria
except with respect to language skills.
Conclusions
Despite the fact that there were no gender differences in
positive toxicology screenings, twice as many men as
women were diagnosed with substance use disorder in the
acute psychiatric department. Use of prescription drugs
with addiction potential was widely under-reported in
both sexes, from patients with no prescriptions for the
medications. Women with no parental responsibility were
overrepresented among those diagnosed with substance
use disorder, as were men with a low level of education.
Abbreviations
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